Bristol-Myers Squibb Co. (BMY) News Nov 20, 2014, 4:20 p.m.
MarketWatch News on BMY
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com
Other News on BMY
Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN 12:00 p.m. Nov. 19, 2014 - InvestorPlace.com
New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma 5:59 a.m. Nov. 19, 2014 - CNW Group
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Nov. 18, 2014 - Seeking Alpha
India Divided on Whether to Break Bristol-Myers Drug Patent 4:48 a.m. Nov. 18, 2014 - The Wall Street Journal Interactive Edition
Yearly Dividend Hikes Aren't Always Necessary In A Successful Dividend Growth Portfolio 4:41 p.m. Nov. 17, 2014 - Seeking Alpha
Incyte Building Blockbuster Drug One Disease At A Time 2:58 p.m. Nov. 17, 2014 - Investors Business Daily
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3 9:57 a.m. Nov. 17, 2014 - Seeking Alpha
Dividend Challengers (And Near-Challengers): 44 Increase Expected By January 31 4:57 a.m. Nov. 17, 2014 - Seeking Alpha
FDA reviewing long-term death risk of antiplatelet therapies 5:08 p.m. Nov. 16, 2014 - Seeking Alpha
Anticlotting Push Urged for Heart Patients With Stents 5:01 p.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers Drug Shows Promise for Skin-Cancer Patients 3:45 a.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers Plans Ireland Plant 6:30 a.m. Nov. 14, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
Ad Comm meeting approaches to discuss risks of epidural steroid injections 11:56 a.m. Nov. 13, 2014 - Seeking Alpha
Analysts' Actions: Bristol-Myers, Broadcom, Jabil Circuit and More 8:23 a.m. Nov. 13, 2014 - TheStreet.com
Morgan Stanley Downgrades Bristol-Myers On Valuation 8:01 a.m. Nov. 13, 2014 - benzinga.com
One Reason Bristol-Myers Squibb (BMY) Stock Is Down Today 8:00 a.m. Nov. 13, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: Applied Materials, Broadcom, Cisco, Genworth, SanDisk and More 7:31 a.m. Nov. 13, 2014 - 247WallSt.com
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination 5:59 a.m. Nov. 13, 2014 - CNW Group
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial 5:59 a.m. Nov. 13, 2014 - CNW Group
Press Releases on BMY
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis 8:31 a.m. Nov. 3, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement 1:00 p.m. Oct. 30, 2014 - BusinessWire - BZX
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers 12:45 p.m. Oct. 30, 2014 - PR Newswire - PRF
The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs 12:00 p.m. Oct. 29, 2014 - PR Newswire - PRF
OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb for PNA-based Therapeutics 8:50 a.m. Oct. 28, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy 7:03 a.m. Oct. 28, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
MarketWatch News on BMY
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:05 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 11:31 a.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 9:49 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 6:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 6:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 6:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 sales $3.92 bln vs. $4.07 bln a year ago 6:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 adj. EPS 45 cents vs. FactSet consensus 42 cents 6:32 a.m. Oct. 24, 2014 - Tomi Kilgore
Mead Johnson Nutrition profit rises 9.5% 7:21 a.m. Oct. 23, 2014 - MarketWatch.com
More than 1/3 of Dow stocks to report this week 4:31 a.m. Oct. 19, 2014 - Wallace Witkowski
Bristol-Myers drops Hepatitis C dual regimen in U.S. 10:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
FDA approves Merck's new-kind of cancer drug 1:58 p.m. Sept. 4, 2014 - MarketWatch.com
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Glaxo chief faces increasing pressure: WSJ 5:29 p.m. Aug. 11, 2014 - MarketWatch.com
Bristol-Myers adjusted profit beats expectations 7:24 a.m. July 24, 2014 - MarketWatch.com
Other News on BMY
Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN 12:00 p.m. Nov. 19, 2014 - InvestorPlace.com
New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma 5:59 a.m. Nov. 19, 2014 - CNW Group
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Nov. 18, 2014 - Seeking Alpha
India Divided on Whether to Break Bristol-Myers Drug Patent 4:48 a.m. Nov. 18, 2014 - The Wall Street Journal Interactive Edition
Yearly Dividend Hikes Aren't Always Necessary In A Successful Dividend Growth Portfolio 4:41 p.m. Nov. 17, 2014 - Seeking Alpha
Incyte Building Blockbuster Drug One Disease At A Time 2:58 p.m. Nov. 17, 2014 - Investors Business Daily
Adexanet Alfa reverses anticoagulant effect of Eliquis in first stage of Phase 3 9:57 a.m. Nov. 17, 2014 - Seeking Alpha
Dividend Challengers (And Near-Challengers): 44 Increase Expected By January 31 4:57 a.m. Nov. 17, 2014 - Seeking Alpha
FDA reviewing long-term death risk of antiplatelet therapies 5:08 p.m. Nov. 16, 2014 - Seeking Alpha
Anticlotting Push Urged for Heart Patients With Stents 5:01 p.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers Drug Shows Promise for Skin-Cancer Patients 3:45 a.m. Nov. 16, 2014 - The Wall Street Journal Interactive Edition
Bristol-Myers Plans Ireland Plant 6:30 a.m. Nov. 14, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
Ad Comm meeting approaches to discuss risks of epidural steroid injections 11:56 a.m. Nov. 13, 2014 - Seeking Alpha
Analysts' Actions: Bristol-Myers, Broadcom, Jabil Circuit and More 8:23 a.m. Nov. 13, 2014 - TheStreet.com
Morgan Stanley Downgrades Bristol-Myers On Valuation 8:01 a.m. Nov. 13, 2014 - benzinga.com
One Reason Bristol-Myers Squibb (BMY) Stock Is Down Today 8:00 a.m. Nov. 13, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: Applied Materials, Broadcom, Cisco, Genworth, SanDisk and More 7:31 a.m. Nov. 13, 2014 - 247WallSt.com
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination 5:59 a.m. Nov. 13, 2014 - CNW Group
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial 5:59 a.m. Nov. 13, 2014 - CNW Group
Press Releases on BMY
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA) 8:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial 3:45 a.m. Nov. 16, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting 8:36 a.m. Nov. 12, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Foundation Awards $2 Million in New Grantsto Help Veterans and their Families Transition from Military to Civilian Life 9:00 a.m. Nov. 10, 2014 - BusinessWire - BZX
Upcoming Conferences, Contract Award, Quarterly Financial Results, and Completion of Acquisition - Research Reports on Bristol-Myers Squibb, 3M, Colony Financial, NOV and PPG 8:40 a.m. Nov. 10, 2014 - PR Newswire - PRF
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis 9:00 a.m. Nov. 8, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives the LEAD Award from The US Oncology Network 10:33 a.m. Nov. 7, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors 8:35 a.m. Nov. 5, 2014 - PR Newswire - PRF
Lexicon Strengthens Clincial Operations And Commercial Readiness 4:15 p.m. Nov. 4, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference 10:00 a.m. Nov. 4, 2014 - BusinessWire - BZX
Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro 8:45 a.m. Nov. 3, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis 8:31 a.m. Nov. 3, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement 1:00 p.m. Oct. 30, 2014 - BusinessWire - BZX
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers 12:45 p.m. Oct. 30, 2014 - PR Newswire - PRF
The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs 12:00 p.m. Oct. 29, 2014 - PR Newswire - PRF
OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb for PNA-based Therapeutics 8:50 a.m. Oct. 28, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy 7:03 a.m. Oct. 28, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
